Stockscreener 앱 받기
2.56
0.79%
0.02
전일 마감가:
$2.54
열려 있는:
$2.54
하루 거래량:
108.40K
Relative Volume:
0.02
시가총액:
$38.70M
수익:
$2.09M
순이익/손실:
$-30.04M
주가수익비율:
-0.7832
EPS:
-3.2685
순현금흐름:
$-27.57M
1주 성능:
-1.54%
1개월 성능:
-8.57%
6개월 성능:
-36.32%
1년 성능:
-74.93%
1일 변동 폭
$2.52
$2.58
1주일 범위
$2.52
$2.67
52주 변동 폭
$2.13
$10.74
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
2.56 | 38.70M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-12-05 | 개시 | H.C. Wainwright | Buy |
| 2024-09-18 | 개시 | Chardan Capital Markets | Buy |
| 2024-07-26 | 개시 | Morgan Stanley | Overweight |
| 2024-02-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
ARMISTICE CAPITAL, LLC Acquires New Stake in CervoMed Inc (CRVO) - GuruFocus
Roth MKM Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits
SABBY MANAGEMENT, LLC's CervoMed Inc(CRVO) Holding History - GuruFocus
CRVO Q2 2026 Earnings: Loss Narrows 27.7% vs Estimates, Shares Dip 6.8%Earnings Cycle Outlook - vinanet.vn
CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares - Stock Titan
CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing - Stock Titan
Woodline Partners (CRVO) discloses 5.1% beneficial stake in CervoMed common stock - Stock Titan
Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund - Stock Titan
CRVO Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.64 Beats Estimates by 27.7%; Shares Slip 4.56% - vinanet.vn
CRVO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $18 - Moomoo
CervoMed at Canaccord Genuity conference: dLB push gains ground By Investing.com - Investing.com Nigeria
CRVO: Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS - TradingView
CervoMed at Canaccord Genuity conference: dLB push gains ground - Investing.com
CervoMed Inc. (CRVO) Surges 9% as Biotech Stock Approaches Key Resistance at $3.28Stop Loss Guidance - dars.gov.et
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
CervoMed reports Q2 2026: $24.9M cash position, net loss $6.6M; advancing neflamapimod toward Phase 3 - TradingView
CervoMed (NASDAQ: CRVO) details Q2 2026 loss, cash runway and DLB program - Stock Titan
Canaccord cuts CervoMed stock price target on funding uncertainty By Investing.com - Investing.com India
CervoMed presents data on DLB treatment at AAIC 2026 - scanx.trade
CRVO Maintained by Canaccord Genuity -- Price Target Lowered to $18 - GuruFocus
CervoMed Q2 Results: EPS Misses Estimate, Losses Widen YoY - scanx.trade
CervoMed Q2 Results: Net Loss Widens To $6.6M, Seeks DLB Partner - scanx.trade
Canaccord cuts CervoMed stock price target on funding uncertainty - Investing.com
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
CervoMed Q2 net loss lower than estimates as costs drop - TradingView
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $18 - Moomoo
CRVO Q2'26 Earnings: revenue estimate is 50.00K USD - TradingView
CERVOMED INC : CANACCORD GENUITY CUTS TARGET PRICE TO $18 FROM $27 - Bitget
CRVO Q2 2026 Earnings: Loss of -$0.64 Beats Estimates by 27.74% but No Revenue ReportedTangible Book Value - vinanet.vn
CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely - simplywall.st
CervoMed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CervoMed Inc. 2026: Revenue $0 Net income ($6.57M), EPS ($0.64) — 10-Q Summary - TradingView
CRVO: Raised $20.5M in June 2026 to fund R&D and strategic partnership for Phase 3 DLB trial - TradingView
CervoMed (NASDAQ: CRVO) raises $20.5M, ends Q2 with $24.9M cash - Stock Titan
CRVO: Neflamapimod progresses to Phase 3 for DLB, with strong cash position and key milestones ahead - TradingView
CervoMed Inc (CRVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CervoMed Inc. (CRVO) Edges Lower to $2.77 as Shares Consolidate Within Tight Trading RangeQuality Factor - dars.gov.et
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - manilatimes.net
CervoMed Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
CervoMed granted UK Innovation Passport for neflamapimod in dementia with Lewy bodies - TradingView
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) - The Manila Times
CervoMed's neflamapimod wins UK ILAP Innovation Passport for DLB - scanx.trade
CervoMed Inc (CRVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CervoMed Inc (CRVO) Cash Flow - TradingKey
CervoMed Inc (CRVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CervoMed Inc (CRVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRVO|CervoMed Inc|Price:2.690|Chg%:+0.030 - TradingKey
CRVO|CervoMed Inc|Price:2.640|Chg%:-0.020 - TradingKey
CervoMed Inc (CRVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cervomed Inc 주식 (CRVO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Winton Matthew | Chief Commercial and Business |
Nov 17 '25 |
Buy |
8.43 |
3,500 |
29,505 |
13,500 |
| Winton Matthew | Chief Commercial and Business |
Nov 18 '25 |
Buy |
7.95 |
1,500 |
11,925 |
15,000 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
12,500 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
1,484,078 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 18 '25 |
Buy |
8.32 |
2,500 |
20,800 |
12,500 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 17 '25 |
Buy |
8.45 |
1,000 |
8,450 |
10,000 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
1,484,078 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
12,500 |
| Gregoire Sylvie | Director |
Nov 13 '25 |
Buy |
7.51 |
4,447 |
33,397 |
1,471,578 |
| Gregoire Sylvie | Director |
Nov 14 '25 |
Buy |
7.57 |
1,707 |
12,922 |
1,473,285 |
0.86%
0.31%
자본화:
|
볼륨(24시간):